FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors

Bao Nguyen(Johns Hopkins University), Donald Small(Johns Hopkins University)

Oncotarget

January 6, 2017

10.18632/oncotarget.14539

Cited by 40

Related Papers

FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation

|Signal Transduction and Targeted Therapy|2021|106

Fatty acid distribution in systems modeling the normal and diabetic human circulation. A 13C nuclear magnetic resonance study.

|Journal of Clinical Investigation|1991|92

IMC-EB10, an Anti-FLT3 Monoclonal Antibody, Prolongs Survival and Reduces Nonobese Diabetic/Severe Combined Immunodeficient Engraftment of Some Acute Lymphoblastic Leukemia Cell Lines and Primary Leukemic Samples

|Cancer Research|2006|44

Targeting rapid <scp>TKI</scp> ‐induced <scp>AXL</scp> upregulation overcomes adaptive <scp>ERK</scp> reactivation and exerts antileukemic effects in <i>FLT3</i> / <scp>ITD</scp> acute myeloid leukemia

|Molecular Oncology|2024|3